Abcellera Biologics earnings were -$167.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ABCL earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$45.6M, up 33.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABCL reported annual earnings of -$162.9M, with 11.2% growth.
Abcellera Biologics Earnings Reports & History FAQ
What were Abcellera Biologics's earnings last quarter?
On ABCL's earnings call on Invalid Date, Abcellera Biologics (NASDAQ: ABCL) reported Q1 2025 earnings per share (EPS) of -$0.15, up 7.14% year over year. Total ABCL earnings for the quarter were -$45.62 million. In the same quarter last year, Abcellera Biologics's earnings per share (EPS) was -$0.14.
Is Abcellera Biologics profitable or losing money?
As of the last Abcellera Biologics earnings report, Abcellera Biologics is currently losing money. Abcellera Biologics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$167.87 million, a 14.28% increase year over year.
What was ABCL's earnings growth in the past year?
As of Abcellera Biologics's earnings date in Invalid Date, Abcellera Biologics's earnings has grown year over year. ABCL earnings in the past year totalled -$167.87 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.